[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599312":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":41,"locations":47,"responsibleParty":62,"collaborators":40,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":40,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":40,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":90,"whyStopped":40,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Minocycline 100mg","EXPERIMENTAL","Capsules Minocycline 100mg po once in the morning and placebo 100mg po once in the evening for 12 months",[13],"Drug: Minocycline 100mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Minocycline 200mg","Capsules Minocycline 100mg po twice a day for 12 months",[18],"Drug: Minocycline 200mg",{"label":20,"type":21,"description":22,"interventionNames":23},"Placebo","PLACEBO_COMPARATOR","Capsules placebo 100mg po twice a day for 12 months",[24],"Drug: Placebo",[26,32,36],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Capsules Minocycline 100mg po per day and placebo 100mg po per day for 12 months",[9],[31],"MRP intervention 1",{"type":27,"name":15,"description":16,"armGroupLabels":33,"otherNames":34},[15],[35],"MRP intervention 2",{"type":27,"name":20,"description":22,"armGroupLabels":37,"otherNames":38},[20],[39],"MRP control",null,[42],{"name":43,"role":44,"phone":45,"phoneExt":40,"email":46},"Dan Liang, Professor","CONTACT","0086-020-87330402","liangdan@gzzoc.com",[48],{"facility":5,"status":40,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Guangzhou","Guangdong","510060","China","CN",{"type":55,"coordinates":56},"Point",[57,58],113.25,23.11667,{"lat":58,"lon":57},[61],{"name":43,"role":44,"phone":45,"phoneExt":40,"email":46},{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"PRINCIPAL_INVESTIGATOR","Liang Dan","Zhongshan Ophthalmic Center","100599312","phase-3-a-multicenter-randomized-double-blind-controlled-clinical-study-of-minocycline-for-the-treatment-of-retinitis-pigmentosa-100599312",false,"NCT07082855","A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa","A Multicenter, Double-Blind, Randomized Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa","Inclusion Criteria:\n\n* Age should be between 18 and 60 years old.\n* Clinically diagnosed with retinitis pigmentosa, characterized by reduced electroretinogram (ERG) responses and constricted visual fields.\n* In at least one eye, the amplitude of the 30Hz flicker ERG under photopic conditions should not be lower than 0 microvolts.\n* The best-corrected visual acuity (BCVA, ETDRS) in both eyes should not be lower than 0.\n\nExclusion Criteria:\n\n* Allergic to tetracycline antibiotics.\n* Pregnant or breastfeeding.\n* Syndromic retinitis pigmentosa.\n* Currently taking tetracycline antibiotics or any medications that may have adverse interactions with minocycline.\n* Currently participating in or having participated in another investigational study within the past 6 months.\n* Presence of other ocular diseases, including glaucoma, uveitis, age-related macular degeneration, diabetic retinopathy, etc.\n* History of ocular surgical intervention.\n* History of uncontrolled severe comorbid conditions, such as renal disease, liver disease, autoimmune disease, thyroid dysfunction, psychiatric disorders, or idiopathic intracranial hypertension.\n* Inability of the participant to comply with the study-required procedures, such as epilepsy, inability to fixate, or allergy to fluorescein. Inability to understand the content of the study, sign the informed consent form, or comply with the study procedures or follow-up visits.\n* Inability to swallow capsules.","ALL","18 Years","60 Years",{"count":77,"type":78},126,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","This is a multicenter, double-blind, randomized controlled clinical trial to get high - level evidence on minocycline's efficacy and safety（100mg\u002Fd, 200mg\u002Fd) for Retinitis pigmentosa and to find the optimal treatment dose.",[84,85,86],"Retinitis Pigmentosa","Inherited Retinal Dystrophy","Retina Disorder",[84,88,89,85],"Minocycline","ERG","NOT_YET_RECRUITING","2025-07-15",{"date":93,"type":94},"2025-07-24","ACTUAL",{"date":91,"type":78},{"date":97,"type":78},"2028-06-30",{"name":5,"class":6},1]